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INTRODUCTION 
Benzodiazepines (BZs),  such as diazepam and chlordiazepoxide, are  safe drugs used to 
controlled anxiety and sleep disorders.1  They have got two different types of receptors 
called:  central  benzodiazepine  receptors (CBRs) and  peripheral  benzodiazepine 
receptors (PBRs). 
• CBRs is present in the brain and forms an allosteric site on the GABAA receptor 
complex.  Some  ligands  acting  at  this  allosteric  site,  as  well  as,  diazepam and 
chlordiazepoxide, enhance the affinity of the γ-aminobutyric acid (GABA) toward 
the CBR and, in this way, influence chloride (Cl-) influx at the GABAA receptor 
pore, causing downstream effects on GABA-mediated inhibition.2
         Other studies have shown benzodiazepines (BZs) acting on CBRs to be responsible 
for different GABAA-induced effects: BZs are used clinically as muscle relaxants, 
anticonvulsants, anxiolytics and sedative-hypnotics.2 This drugs have got numerous 
collateral effects, for example: ethanol potentiation, amnesia, ataxia, dizziness and 
the risk of dependence if used for too time.1
• PBRs is first described by Braestrup and Squires4  in 1977, as an alternative binding 
site in non-neuronal tissue for the diazepam, a centrally acting benzodiazepine. It 
was  named  peripheral  according  to  this  tissue  distribution  and  benzodiazepine 
receptor because BZs is the class of ligands by which PBR was discovered. Other 
names  have  been  used  to  refer  to  this  protein,  including  mitochondrial  
benzodiazepine receptor (MBR), mitochondrial diazepam binding inhibitor (DBI)  
receptor  complex (mDRC),  PK11195 binding sites  (PKBs),  isoquinoline binding  
protein (IBP), Omega3 (ω3) receptor. 5
Although the name PBR was much used in the scientific community, in 1996 it change in 
the  new  name  Translocator  Protein  18  kDa,  abbreviated  TSPO,  proposed  by 
Papadopoulos  and  colleagues6 because  it  didn’t  take  into  account  the  new  findings 
regarding its structure, subcellular roles and tissue distribution. It has also been shown that 
many ligands structurally different  from BZs bind to this  protein,  which is  not  a  very 
receptor  in  the  traditional  sense,  but  rather  a  translocator  of  molecules  as  well  as 
cholesterol  and protoporphyrins.  In  this  thesis  work is  adopted the abbreviation  TSPO 
instead of PBR.
 
Braestrup and Squires 4 during their pharmacological studies, noticed a specific binding of 
[3H] diazepam to receptors in rat kidney, liver and lung, but at the same time observed that 
binding in non-neuronal tissue appeared to be very different from the specific binding to 
brain  membranes:  first,  while  binding  in  kidney  was  associated  with  mitochondrial 
fraction,  in  brain  it  was  associated  with a  membrane fraction;  second,  the  affinity for 
receptors in kidney was lower than that for brain binding sites.
In 1982 Marangos et al.  confirmed that TSPO has a brain regional distribution distinct 
from that of CBR and that it is not linked to GABA-regulated anion channels.7   Receptor 
binding was assayed using diazepam, that has got high affinity to CBR and weakly with 
1
TSPO  and  the  Ro  5-4864  (7-chloro-1,3-dihydro-1-methyl-5-(p-chlorophenyl)-2H-1,4-
benzodiazepine-2-one), which differs from diazepam only by a chloride in the 5' aromatic 
ring and that has a nanomolar  affinity for TSPO (7.3nM)  8  but a very low affinity for 
GABAA receptors (163 μM9  in rat brain membranes) (Figure 1).
         Diazepam (1)                           Ro 5-4864 (2)
Figure 1. Diazepam (1) and Ro 5-4864 (2) 
Following studies have determined the high mitochondrial localization of TSPO and the 
smaller  concentration  in  some subcellular  compartments  as  well  as  plasma membrane, 
lysosomes, peroxisomes, nuclei and Golgi apparatus.
In 1986 Anholt and co-workers investigated the submitochondrial localization of TSPO, 
using cytochrome oxidase as marker for the inner membrane and monoamine oxidase as 
outer membrane marker. Treating rat adrenal mitochondria with digitonin, a detergent able 
to separate the outer membrane from the inner membrane, they noticed that the release of 
TSPO increased parallel to the release of monoamine oxidase and provided evidence for 
the association of TSPO with the mitochondrial outer membrane.10
Following studies have determined that TSPO is very concentrated in a particular sites 
called  mitochondrial  permeability  transition pore abbreviated  MPTP and  exactly  at 
contact sites between the outer/inner mitochondrial membranes.11
 
                                                                                                                                                           
2
Cl N
N
O
Cl N
N
O
Cl
     Structure of TSPO
TSPO is a protein with a molecular mass of 18 kDa, that was identified in 1988 by 
Antkiewicz-Michaluk et al.12 using photolabeling studies, from the rat adrenal gland. It is a 
very hydrophobic and tryptophan-rich protein of 169 amino acids highly conserved 
throughout species. Three-dimensional modeling has revealed a structure with five 
transmembrane domains consisting of α-helices composed of 21 residues that span the 
entire membrane bilayer, with a carboxyl-terminal tail located outside the mitochondria 
and an amino terminal inside the mitochondria 13 ,14 (Figure 2). Following, topographic 
studies have demostrate that the 18 kDa TSPO protein is organized in clusters of four to six 
molecules to form a single pore, reflecting the recognized function of transporter in the 
mitochondrial membrane.15
Figure 2. Molecular structure of 18kDa TSPO and localization at the contact site between the outer 
and inner mitochondrial membrane. It is also shown some proteins associated with TSPO in the 
MPTP complex (VDAC, ANT and PRAX-1).13
McEnery et al. in 1992 discovered that  TSPO is strictly associated in a trimeric complex 
with :
• ANT, adenine nucleotide translocase, a specific antiporter of 30 kDa, located in 
the inner mitochondrial membrane, for the exchange of ATP and ADP as part of 
oxidative phosphorylation.
•  VDAC, a voltage-dependent anion channel of 32 kDa located at sites of contact 
between  outer  and  inner  mitochondrial membrane  that  acting  as  a  channel 
allowing  passage  of  small  molecules  and ions  into  the  mitochondria.13,14  These 
three  subunits  constitute  together  with  other  proteins,  the  mitochondrial 
permeability transition pore, abbreviated MPTP. 16
There are four cytosolic TSPO-associated proteins which most of time play an important 
role in the biological processes where TSPO is involved:
• p10 is  the  first  cytosolic  protein  associated  to  TSPO  identified,  but  whose 
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biochemical  role  has  not  been  understood  yet.  It  is  a  protein  of  10  kDa that 
coimmunoprecipited with 18 kDa TSPO using the isoquinoline carboxamide ra-
dioactive  probe  PK14105,  a  ligand  selective  for  mitochondrial  benzodiazepine 
receptors, to photolabel rat mitochondrial preparations. 17
• PKA-associated protein 7 (PAP7) is a cytosolic protein with a molecular mass of 
52 kDa involved in the hormonal regulation of steroid formation, interacting with 
both the cytosolic RIα  subunit of PKA and TSPO. Particularly, PAP7 targets the 
PKA isoenzyme,  linked  to  increased  steroid  synthesis,  which  phosphorylating 
specific  protein  substrates  induces  the  reorganization  of  TSPO topography  and 
function. 20
• Steroidogenic Acute  Regulatory Protein  (StAR), that  mediates  the  flow  of 
cholesterol from the outer to the inner mitochondrial membrane, permitting steroid 
formation in steroidogenic cell. Following studies indicated that StAR acts at the 
outer  mitochondrial  membrane  and  it  is  not  needed  to  allowed  the  entry  of 
cholesterol into mitochondria. Therefore, Hauet et al. suggest that TSPO and StAR 
work in  concert  to  bring  cholesterol  into  mitochondria  and in  particular  TSPO 
serves as a gatekeeper in cholesterol import into mitochondria and StAR plays the 
role of the hormone-induced activator. 19,20
• PBR  associated  protein-1  (PRAX-1) is  isolated,  cloning  and  characterized  by 
Galiègue et al. in 1999. 21 It is a protein of 1857 amino acids with a molecular mass 
of 240 kDa, discovered using the yeast two-hybrid screening strategy. Exhibiting 
various  domains  involved  in  protein-protein  interaction,  such  as  proline-rich 
domains,  leucine-zipper  motifs  and  Src  homology  region  3-like  (SH3-like) 
dodomains, it has been suggested that PRAX-1 acts as an adaptor protein to recruit 
additional targets to the vicinity of TSPO so as to modulate its function. In addition, 
it was assumed that a single PRAX-1 protein interacts with the C-terminal end (14 
amino acids) of several molecules of TSPO (at least two of them) (Figure 3). 
Figure 3. Hypothetical model of the interaction between TSPO and PRAX-1.21
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Distribution of TSPO
The expression of TSPO is ubiquitary, although it considerably varies among tissues, for 
example is different between peripheral tissues and central nervous system (CNS). An high 
density of TSPO is found in secretory and glandular tissues, such as adrenal glands, pineal 
glands, salivary glands, olfactory epithelium, ependyma and gonads, therefore in steroid 
producing tissues. Intermediate levels of TSPO are detected in renal and myocardial 
tissues; in contrast, the brain (in particular glia, microglia and reactive astrocytes) and liver 
express in normal condition relatively low levels of this protein. TSPO are also found 
among all human peripheral blood leukocyte subsets, particularly in monocytes, 
polymorphonuclear cells and lymphocytes, and in mature human erythrocytes.14
Other  example  of  periperal  tissues  in  with  TSPO  is  present  are:  heart,  liver,  kidney, 
immune system and lung.5
TSPO  density  can  be  modulated  under  a  variety  of  physiological  or  pathological 
conditions.  In  fact,  TSPO is  generally  highly expressed  in  steroidogenic  cells  such  as 
testicular and adrenocortical cells; elevated levels of TSPO, compared to healthy human 
tissues, have also been detected in cancerous tissues of the breast, ovary, colon, prostate, 
and brain glial tumor cells. It has also been supposed a correlation between TSPO levels 
and the metastatic potential of human breast cancer and brain gliomas.22
TSPO  is  upregulated  in  brain  injury  and  inflammation,  in  various  neuropathological 
conditions  (certain  types  of  epilepsy,  stroke,  herpes  and  HIV  encephalitis)  and 
neurodegenerative disorders (Alzheimer’s disease, multiple sclerosis, amyotrophic lateral 
sclerosis,  Parkinson’s  disease  and  Huntington’s  disease).  Moreover,  TSPO  levels  are 
decreased in  patients  with  generalized  anxiety (detected  in  lymphocytes  and platelets), 
panic,  post-traumatic  stress  and  obsessive-compulsive  disorders.  Changes  in  TSPO 
expression have been observed during ischemia-reperfusion injury,  indicating a role for 
TSPO in maintaining kidney function and renal protection. 19, 22, 23
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     Functions of TSPO
TSPO is  involved  in  numerous  biological  processes  as  well  as  regulation  of  immune 
functions, cholesterol transport,  lipid metabolism, steroidogenesis,  calcium homeostasis, 
cell  growth  and  differentiation  mitochondrial  oxidation  and  regulation  of  immune 
functions. 14,24
➢ IMMUNOMODULATION:  TSPO  has  got  an  important  role  in  host  defense 
mechanisms  and  inflammatory  response.  It  is  expressed  in  a  numerous  cells 
involved in the regulation of the immune responses as well  as microglia,  blood 
monocytes and leukocytes. Some TSPO ligands, mainly benzodiazepines, have an 
immunosuppressive action, inhibiting the capacity of macrophages to produce ROS 
(reactive oxygen species) and inflammatory cytokines as well as IL-1 (interleukin-
1),  TNFα  (tumor  necrosis  factor  alpha)  and  IL-6,  and  regulating  phagocyte 
oxidative metabolism required for elimination of foreign antigens.16 Furthermore, 
this antiinflammatory action TSPO-mediated is also due to its capacity of stimulate 
glucocorticoid synthesis in steroidogenic organs and in local tissue damage.5
            TSPO is mainy expressed in CNS in  microglia and in astrocytes.
            Several studies have demonstrated that under conditions resulting in glialactivation, 
as  well  as  inflammation  and  metabolic  stress,  basal  levels  of  TSPO in  these  
cells can increase in a time-dependent manner. This up-regulation of TSPO has  
been  observed  in  traumatic,  ischemic  and  chemically-induced  brain  injury,  in  
neurodegenerative  disorders,  i.e.,  in  the  temporal  cortex  from  patients  with  
Alzheimer’s disease and  Huntington’s disease, in the epilepsy, multiple sclerosis 
and experimental autoimmune encephalomyelitis.14
Activation  of  microglia  consists  in  migration  to  the  site  of  damage,  
proliferation,  production  and  release  of  potent  neuroinflammatory  cytokines  
(TNFα,  IL-1β),  arachidonic  acid  derivatives  as  well  as  cyclooxygenase-
2,excitatory  amino  acids,  and  ROS.  As  inflammatory  responses  mediated  by  
the activation of microglia may aggravate in neuronal damage, and TSPO has  
proved to  be  a  promising  marker  for  activated  microglia,  it  has  attempted  to  
develop specific TSPO ligands able to prevent or limit neuroinflammation or to  
label  the  same  activated  microglia  to  track  the  progression  of  
neuroinflammation.16
➢ APOPTOSIS:  MPTP plays  an  important  role  in  the  modulation  of  signaling 
pathways mediating apoptotic and necrotic cell death. 
The  exact  composition  of  the  MPTP is  not  yet  established,  but  it  has  been  
recognized various proteins implicated in pore formation and its regulation (Figure 
4): an hexokinase, in the cytosol; a trimeric complex constituted by VDAC, ANC 
and TSPO; a creatine kinase in the intermembrane space and cyclophilin D in the 
matrix. 
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Figure 4.  Schematic structure of the MPTP.14
MPTP allows  the  transfer  of  solutes,  including  ATP/ADP exchange,  from  the 
mitochondrial matrix to cytosol, through the VDAC/ANC conduit, and therefore 
facilitates the crossing of the highly impermeable mitochondrial inner  membrane. 
This periodic transient increase in permeability by the MPTP allows the pumping 
of protons from the inner membrane by the electron transport chain and creates the 
transmembrane electrochemical gradient that drives ATP synthesis. 14, 16
Other factors cause the opening of the MPTP: high [Ca2+], low adenine nucleotide 
concentrations, high phosphate concentrations, oxidative stress and pro-apoptotic 
proteins as well as Bcl-2. Pore opening leads to the dissipation of transmembrane 
electrochemical gradient, uncoupling of mitochondria and swelling, resulting in the 
release of cytochrome c and apoptosis inducing factor (AIF) into the cytosol. Once 
in the cytosol, the first induces the caspase cascade ending in the destruction of cell 
nucleus,  cytoskeleton  and  plasma  membrane;  the  second  principally  leads  to 
nuclear chromatin condensation, DNA fragmentation and then to cell death.14
TSPO is an endogenous modulator of apoptotic process but the exact molecular  
events involved have not yet been definitively clarified. There are two different  
types of possible mechanisms for regulating the apoptotic pathway by TSPO. One 
of this is illustrated in Figure 5.  The first types of this mechanisms was supposed 
in 2008 by Veenman et al.  26  They suggested that interaction between VDAC and 
TSPO  is  fundamental  to  initiate  the  mitochondrial  apoptosis  pathway.  The  
intermediary agent between TSPO and VDAC was supposed to be provided by  
mitochondrial ROS  generation under  the control  of  the  same TSPO. ROS lead  
first to dissociation of cytochrome c from oxidized cardiolipins located at the inner 
mitochondrial  membrane  and,  subsequently  to  its  release  in  the  cytosol  via  
formation of a pore due to assemblage of VDAC molecules. 
7
Figura 5. TSPO regulation of the mitochondrial apoptosois pathway.  26
Another possible mechanism was proposed in  2007 by Azarashvili  et  al.27 that  
provided evidence for TSPO involvement in MPTP opening, controlling the Ca2+-
induced  Ca2+ efflux  and  AIF  release  from  mitochondria,  important  stage  of  
initiation of  programmed cell death. 
It has also been observed a modulation by TSPO of interactions between VDAC or 
ANT and pro-apoptotic (Bcl-2) or anti-apoptotic proteins (Bax). 28
Therefore, it has been designed TSPO ligands with pro-apoptotic effects acting as  
anticancer agents. In 2005 Chelli et al.30 proposed PIGA, a ligand chosen from the 
N,N-dialkyl-2-phenylindol-3-ylglyoxylamide  series,  as  a  novel  pro-apoptotic  
compound  with  therapeutic  potential  against  glial  tumours.  TSPO-binding  
ligands  have  also  been  widely  explored  as  carrier  for  receptor-mediated  drug  
delivery, as well as TSPO ligand-Ara-C conjugates30 and Pt complexes.31
➢ STEROIDOGENESIS: The  most  extensively  characterized  function  of  TSPO 
concerns its role in steroid biosynthesis. Two important observations suggest that 
TSPO plays an important role in steroidogenesis: first, the location of this protein 
on the outer mitochondrial membrane and second, the extremely high density in 
steroidogenic endocrine tissues, as well as adrenocortical cells and Leydig cells. 
Different publications report that TSPO ligands stimulate steroid biosynthesis  in 
adrenal, placental, testicular, ovarian and glial systems. 32, 33
The  biosynthesis  of  steroids  begins  with  the  enzymatic  transformation  of  
cholesterol  into  pregnenolone,  which  occurs  through  cholesterol  side-chain  
cleavage by the cytochrome P450scc  (also  known  as  CYP11A1)  and  auxiliary  
electron  transferring  proteins,  localized  on  the  matrix  side  of  the  inner  
mitochondrial  membrane (Figure 6).  Pregnenolone then leaves mitochondria to  
move to the endoplasmic reticulum, where it is transformed in the final steroid  
products. 6, 16, 19
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The rate-limiting step is the translocation of cholesterol from the cellular stores  
across the aqueous intermembrane space to the inner mitochondrial membrane and 
P450scc (cytochrome P450 side-chain cleavage).
Figura 6. TSPO facilitating mitochondrial cholesterol delivery regulates the synthesis of steroids.6
Knockout  and  antisense  experiments  in  vitro have  demonstrated  that  down-
regulation of TSPO causes a decrease in steroid synthesis. 16, 32, 33
The topographic study of TSPO in the mitochondrial membranes have also shown 
that after treatment of Leydig cells with a steroidogenesis stimulator, as well as  
choriogonadotrophin hormone (hCG), there are various morphological changes,  
for example a formation of large complexes of 15-25 molecules of TSPO and a  
rapid reorganization of their localization in the mitochondrial membrane, as well  
as a rapid increase in TSPO ligand binding. 16, 32
Amino  acids  deletion,  site-directed  mutagenesis  and  structural  studies  have  
permitted to identified a  cholesterol recognition amino acid consensus (CRAC)  
sequence in the cytosolic carboxy-terminal domain of the TSPO that could be part 
of the binding site for the uptake and translocation of cholesterol (channel-like  
interaction)  through  a  channel  delimited  by  five  α-helixes  of  TSPO.  Besides,  
for cholesterol delivery into mitochondria  TSPO-mediated  is  also  required  the  
interaction of TSPO with StAR, as referred  above,  a  protein  acting  as  
hormoneinduced activator.  6, 16, 32
It  has  been observed a relationship between steroid levels,  TSPO levels and   
anxiety, principally due to the fact that neurosteroids are endogenous modulators  
of the GABAA receptor (Figure 7). 
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Figura 7. Schematic representation of TSPO-mediated regulation of neurosteroid biosynthesis and 
its role in neurological disorders.19
TSPO levels, determined by radioligand binding to platelets, decrease in patients  
with  anxiety  disorders.  Therefore,  ligands  binding  to  TSPO  located  in  glial  
cells, as well as N,N-dialchyl-2-pheniylindol-3-ylglyoxylamides synthesized by Da 
Settimo et al.34, provide the cholesterol necessary to restore neurosteroid synthesis 
and  increase  pregnenolone  formation,  which  is  then  metabolize  to  form  
allopregnanolone, a potent allosteric modulator of the GABAA exerting anxiolytic 
effects.  For this  reason,  TSPO could be considering a promising target  for the  
psychiatric disorders that involve dysfunction in steroid biosynthesis.19, 35
➢ Other Functions:  TSPO has  got  other  functions,  for  example:  protein  import, 
important for membrane biogenesis and in fact  TSPO is necessary for the import 
of StAR protein into mitochondria;  TSPO binding of dicarboxylic porphyrin and  
transport  into mitochondria and in particular the relationship between TSPO and 
heme  biosynthesis  pathway;  ion  transport  and  calcium  homeostasis  (TSPO 
regulates the Ca2+ flow into the cell); TSPO has got an important role in  cellular  
respiration, mitochondrial oxidation,  cellular proliferation and differentiation in a 
number of cell types.6  TSPO can modulate responses to viral infections. In fact, 
pathogenic  virus  targets  TSPO  to  inhibit  dissipation  of  the  transmembrane 
mitochondrial potential and prevents the release of  cytochrome c, resulting in the 
blockade  of  apoptosis  and  overcoming  of  the  host  responses  against  viral 
infections.28
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     TSPO Ligands
TSPO has got two different types of ligands: endogenus and synthetic. 
• Endogenus Ligands: a numerous types of endogenous molecules with affinity for 
the TSPO and different chemical structures have been identified. 
Protoporphyrins  (protoporphyrins IX, mesoporphyrins IX, deuteroporphyrins IX, hemin) 
have got a high affinity for TSPO. As several steroidogenic tissues, as well as the adrenal 
gland  and  testis,  show  high  TSPO  and  porphyrin  levels,  it  has  been  suggested  a 
physiological role for the interaction of these two molecules. Furthermore, having a plane 
of symmetry (Figure 8), these molecules could bind dimerized form of TSPO, confirming 
in this way the postulated two-binding site model. 16, 33
 (3)                                              (4)
Figure 8. Chemical structures of protoporphyrin IX (3) and heme (4). 
Cholesterol is a important ligand as previously reported discussing the fundamental role of 
TSPO in the regulation of cholesterol transport and thus in the steroidogenesis. Again it has 
been  shown that  a  dimeric  form of  TSPO possesses  an  enhanced  binding  capacity  to 
cholesterol.33
In 1984 Corda et al. isolated and purified a neuropeptide able to inhibit diazepam binding 
to BZ binding site on brain membranes. This 11 kDa polypeptide, named DBI (diazepam 
binding inhibitor), is constituted by 86 amino acids and binds with low affinity both TSPO 
and CBR, while a short fragment of DBI, triakontatetra-neuropeptide, is more selective for 
TSPO. Furthermore, DBI promotes loading of cholesterol to the cytochrome P450scc and 
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stimulates steroidogenesis by directly interacting with TSPO.32, 33
Anthralin    is a 16 kDa protein that has been demonstrated interact with both TSPO and 
dihydropyridine  binding  site,  and  phospholipase  A2 have  also  been  proposed  as 
endogenous ligands for TSPO.33
• Synthetic Ligands:  this ligands have been developed with the aim to deepen the 
knowledge of the exact pharmacological role of TSPO, to define its involvement in 
several pathophysiological conditions and to establish the structural requirements 
needed for an optimum of affinity. 
Initially,  the  most  of  these  ligands  have  been  designed  starting  from classical  
selective CBR ligands, as well as benzodiazepines, making the necessary structural 
modifies in order to shift the affinity toward TSPO. Until to date the prototypic  
ligands, used as reference compounds in the development of TSPO pharmacophore 
models and in SAR (structure-activity relationship) studies, are the benzodiazepine 
Ro  5-4864  (2)  and  the  isoquinolinecarboxamide  PK11195  (5),  classified  by  
LeFur  and  coworkers  the  first  as  a  TSPO  agonist  or  partial  agonist  and  the  
second as an antagonist.16
Then, a number of diversified structures have been developed with good results of 
affinity  and  selectivity,  and  leading  to  drawing  various  TSPO pharmacophore  
models useful for designing novel synthetic derivatives. Therefore, the topology of 
the TSPO binding cleft has not yet been completely defined.5
TSPO specific synthetic ligands do not have a typical shared structure and thus can 
be distinguished nine different classes of compounds (Figure 9).
1) Benzodiazepines: in this class the selectivity toward the TSPO or CBR results very 
sensitive  even  to  slight  structural  modifications:  in  fact,  as  described  earlier  in 
Figure 1,  in  the  case  of  Ro 5-4864  (2)  the  insertion  of  a  chlorine  at  the  para 
position  of  the  pendant  phenyl  rings  of  the  diazepam,  equipotent  at  the  two 
receptors, shifts the selectivity toward TSPO. Ro 5-4864 has been used in a number 
of studies aimed at characterizing TSPO, and particularly by Gavioli and colleagues 
to  study the  putative  role  of  TSPO as  a  target  for  the  treatment  of  psychiatric 
disorders.5
2) Isoquinolinecarboxamide  PK 11195  (5)  is  the first  non-benzothiazepine ligand 
binding the TSPO with nanomolar affinity and it is widely used for studies aimed to 
define and map the binding site. In 2008, Chelli et al.36 showed that treatment of a 
human astrocytoma cell line (ADF) with PK 11195 actives an autophagic pathway 
followed by apoptosis mediated by mitochondrial potential dissipation. Moreover, 
has  been showed that  PK 11195 has a  multidrug resistance modulating activity 
increasing the efficacy of a daunorubicin treatment on human multidrug-resistant 
leukemia  cell  line  in  vitro by  5-7  fold  and  blocking  p-glycoprotein  efflux,  a 
transporter whose activity contributes to limit antitumor drug efficacy.28
3) Alpidem  (6)  can be considered the progenitor of the class of  imidazopyridines 
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known to bind both TSPO and CBR with the nanomolar affinity (Ki 0.5-7 nM and 
1-28 nM, respectively).5
4) Phenoxyphenylacetamide derivatives, such as DAA1097 (7), were designed by a 
process of molecular simplification involving the opening of the diazepine ring of 
Ro 5-4864.  Some compounds  of  this  class  of  TSPO ligands have  also  showed 
potent anxiolytic properties in laboratory animals.5
5) Pyrazolopyrimidineacetamides, i.e. DPA714  (8), were first described by Selleri 
and coworkers as bioisosters of the imidazopyridines and thereby closely related to 
alpidem.5
6) Indoleacetamide  derivatives, collectively named FGIN-1  (9),  was developed by 
Kozikowski and colleagues as a new class of compounds binding with high affinity 
and selectivity for TSPO. 5 In a recent study SSR180575 (10), an indoleacetamide 
compound, was shown to have neuroprotective properties in different models of 
progressive  degeneration  of  the  PNS and  CNS:  precisely  it  promotes  neuronal 
survival and repair following axotomy through the regulation of apoptosis of glial 
cells and/or the production of mediators such as neurosteroids, cytokines or other 
neurotrophic factors that support nerve survival.28
PK 11195 (5)                     Alpidem (6)                DAA1097 (7)
  DPA714 (8)                        FGIN-1 (9)                          SSR180575 (10)
Figure 9. Structures of the some representative ligands of the most important classes of 
compounds selective for TSPO. 
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7) Benzothiazepines, a class of TSPO ligands featuring a 6,7 bicyclic nucleus, were 
initially developed by Campiani and coworkers as selective ligands for CBR and 
GABA receptor  subtypes.  Some pyrrolobenzothiazepines  derivatives  possess  an 
unexpected significant inhibitory activity at L-type calcium channels, equal to or 
higher than those of reference calcium antagonists such as verapamil and (+)-cis-
diltiazem.5
8) On  the  basis  of  pyrrolobenzothiazepine  skeleton,  the  pyrrolobenzoxazepine 
scaffold has been developed, featuring the replacement of the endocyclic sulfur (S5) 
with an oxygen (O5), that increases affinity by 2-3 fold. Some of these compounds 
showed  an  high  affinity  toward  the  TSPO  (Ki values  in  the  low  nanomolar-
subnanomolar range) and the capacity to stimulate steroidogenesis in mouse Y-1 
adrenocortical cell line.5
9) Indol-3-ylglyoxylamides (this class is treatise in the next section).
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N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides
In 2004 Primofiore et al.37 prepared and tested a series of  N,N-dialkyl-2-phenylindol-3-
ylglyoxylamide derivatives  I  (Table 1)  as TSPO ligands,  designed as conformationally 
constrained analogues of the indoleacetamides of the FGIN (9) series previously described 
by Kozikowski and coworkers.  Most of these compounds showed a high affinity for TSPO 
in the nanomolar to subnanomolar range and a high selectivity for TSPO over CBR. The 
TSPO/CBR selectivity was evaluated by binding studies using membranes from rat brain 
tissues  and  [3H]flumazenil  as  radioligand.  For  some of  these  TSPO ligands  with  high 
affinity,  the  ability to  stimulate  pregnenolone formation  from rat  C6 glioma cells  was 
evaluated. 
In Table 1 has been reported the binding affinity of compounds Ia-Iaah (data taken from 
ref. 34, 37) and of the standard TSPO ligands Ro 5-4864 (2), PK 11195 (5) and alpidem 
(6), expressed as Ki values. 
It has been observed that, among the unsubstitued derivatives Ia-Im (R3 = R4 = R5 = R6 = 
H), N-monosubstitued compounds  Ia-Ib  show the lowest affinity probably because they 
cannot occupy both the L3 and L4 lipophilic pockets. 
The N,N-disubstitued indolylglyoxylamides instead exhibit a high affinity and in particular 
compound  Ig,  bearing  two  n-hexyl  groups,  is  the  most  potent,  with  a  Ki of  1,4  nM. 
Therefore,  increasing  the  length  of  the  linear  N-alkyl  groups  has  been  observed  an 
enhancement of affinity, due to the better filling of L3 and L4 lipophilic pockets. 37
The  three  derivatives  Id,  Ie,  Ig  and  Ij  has  been  selected  as  leads  for  further  affinity 
optimization efforts. It has been observed that: 5,  34, 37
– The  insertion  of  an  electron-donating  lipophilic  group,  as  well  as  a  methyl 
group (Idd-Igg), in the 4’-position (R3) of the 2-phenyl ring does not produce 
any gain in affinity respect to the parent unsubstitued compound. Introducing an 
electron- withdrawing substituent as well as Cl, F, NO2 and CF3 (In-Icc), it has 
been instead obtained compounds with higher affinity, and among these ones, 
the  N,N-di-  n-hexyl derivatives  Ip  (Cl),  It  (F),  Ix  (NO2) and  Ibb  (CF3) have 
been revealed the most potent, with Ki values of o.37 nM, 0.55 nM, 0.27 nM 
and 1 nM, respectively. These results suggest that the R3  substituent has to be 
electron-withdrawing to reinforce the putative  π-stacking interaction with an 
electron-rich aromatic ring within the L1 pocket.
– The data  of  affinity of  compounds  Ihh-Iww  bearing a  substituent  in  the 5-
position of the indole nucleus (F, Cl, NO2,  OCH3) suggest that R6 has to be 
electron-withdrawing and also very small for optimal binding, and only Ijj with 
a fluorine at the 5-position features these properties (Ki = 0.37 nM).
– The introduction of two halogens in  both 4’-  and 5-positions (Ixx-Iiii;Ivvv-
Iyyy)  does  not  increase  affinity  in  additive  manner,  but  it  has  supposed  a 
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correlation with the nature of the N,N-dialkyl chain.
– Substitutions  at  the  7-position  of  the  indole  nucleus  (R5)  with  an  electron- 
withdrawing  (Cl,  Ijjj-Immm)  or  an  electron-donating  (CH3,  Innn-Iqqq) 
lipophilic group do not produce any gain in affinity. 
– The binding data of asymmetrical N,N-dialkyl derivatives (Irrr-Iaah), designed 
to probe the L3 and L4 lipophilic pockets at the TSPO binding site, indicate that 
the L3 and L4 pockets are probably different in their dimensions, and that R1 
and R2 have to be of different size to obtain the bestperforming substitution on 
the  amide  nitrogen.  Therefore,  an  aromatic  moiety  on  R1/R2 substituents  is 
equivalent to an aliphatic  moiety of similar size in interacting with the two 
lipophilic pockets. 
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Table 1. TSPO binding affinity of N,N-dialkylindolylglyoxylamide derivatives Ia-Iaah. 
         I
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[a] The concentration of tested compounds that inhibited [3H]PK 11195 binding to rat kidney 
mitochondrial membranes (IC50) by 50% was determined with six concentrations of the 
displacers,  each  performed  in  triplicate.  Ki  values  are  the  mean  ± SEM of  three  de-
terminations.  [b]The inhibition percent of  [3H]flumazenil specific binding at 10 μM of the 
compound are the mean ± SEM of five determinations. Ki values are the mean ± SEM of 
three determinations. [c] Data take from ref. 34, 37. 
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In 2008 Da Settimo et al.  34 refined TSPO pharmacophore/topological model through the 
synthesis and the biological evaluation of novel indole derivatives with the general formula 
I, bearing different combinations of substituents R1-R6. 
The SARs of these compounds were rationalized in light of a pharmacophore/topological 
model of TSPO binding site made up of three lipophilic pockets (L1, L3 and L4) and a H-
bond donor group (H1) (Figure 10). Specifically: 
1. the second carbonyl group of the oxalyl bridge engages an H-bond with the donor 
site H1;
2. the two lipophilic substituents R1 and R2 (linear or ramified alkyl, arylalkyl group) 
on  the  amide  nitrogen  interact  hydrophobically  with  the  L3  or  L4  lipophilic 
pockets;
3. the 2-phenyl group establishes π-stacking interactions within the L1 pocket.
 
      PK 11195         N,N-dialkyl-2-phenylindol-3-ylglyoxylamies (I)
Figure 10. TSPO pharmacophore/topological model. 
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     TSPO and PET 
Molecular probes
Diagnostic imaging is referred to different imaging modalities and technologies, as well as:
• Radiography; 
• Nuclear Imaging: 
◦ PET (Positron Emission Tomography); 
◦ SPECT (Single Photon Emission Computed Tomography); 
◦ PET/CT (PET/Computed Tomography combination). 
• Magnetic Resonance Imaging (MRI); 
• Optical Imaging
◦ fluorescence;
◦ near-infrared or NIR. 
• Diagnostic Ultrasounds.
Some of these imaging methods are based on use of molecular probes and for this reason 
can  be  called  “molecular  imaging” modalities.  Molecular  probes  can  be  referred  to 
radiolabelled molecules or fluorescent ligands designed for in vitro or in vivo application, 
able to form covalent bindings with apposite constituents of receptor (affinity labels) and 
therefore useful for determination and characterization of a receptor by various chemical-
physical techniques. 
Molecular probes consist of two parts: 35
1. a  radioactive  nuclide  or  a  fluorophore  group,  responsible  for  a  signal  detectable 
outside of the organism for visualization with nuclear medical methods or fluorescent  
spectroscopy;
2. a  molecular  structure  (vector,  ligand,  vehicle),  that  defines  the  biological 
characteristics and is responsible for chemical and biochemical interactions within 
the  living  organism,  influencing  in  this  way  pharmacokinetic  and 
pharmacodynamic parameters.
Since  they  are  chemically  indistinguishable  from their  non-radioactive  counter-
parts,  molecular  probes  either  interact  directly  with  specific  target  sites  and 
processes (substrates for enzymes, ligands for receptors or transporters) or take part 
directly in metabolic processes. For these reasons they can be used for in vitro or in 
vivo visualization, characterization and quantification of biological processes at the 
cellular and subcellular level.38
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Molecular imaging is also a non-invasive biomedical instrument useful for the diagnosis 
and monitoring of cardiac pathology, different forms of cancer and neurological diseases. 
Imaging methods also allows monitoring the progression of a pathology in a specific 
patient, permitting an approach of personalized therapy and visualizing a pathological 
change on the molecular level resulting in abnormal function long before morphological 
manifestation.38
Molecular probes used for TSPO
The density of TSPO is much increased in several human pathologies, such as gliomas and 
neurodegenerative disorders, for example Huntington’s and Alzheimer’s diseases, as well 
as  in  various  forms  of  brain  injury  and  inflammation.  TSPO  is  also  up-regulated  in 
neuroinflammatory conditions mediated by microglial activation. Changes in TSPO levels 
have also been detected in  patients affect  by generalized anxiety,  panic,  post-traumatic 
stress, obsessive-compulsive disorders, and separation anxiety. 39
For this reasons, TSPO has been suggested as a promising diagnostic marker to image and 
measure the TSPO expression and distribution levels in living cells, isolated tissues, or 
living  subjects,  and  then  for  evaluation  of  disease  progression  by  mean  of  specific 
fluorescent or radiolabeled ligands. 
PET imaging using TSPO ligands to label activated microglia offers quantitative measures 
of inflammation and then can help to understand the regional brain distribution, stage and 
severity  of  neuroinflammation,  so  can  be  considered  a  valuable  tool  to  determine 
individual approaches to treatment of disease. 39
Fluorescent ligands is a alternative to radioligands for investigating the localization and the 
expression  level  of  TSPO.  In  2010  Taliani  and  coworkers41 developed  novel  potent, 
selective and irreversible fluorescent probes introducing a NBD-fluorophore (7-nitrobenz-
2-oxa-1,3-diazol-4-yl)  and  an  electrophilic  isothiocyanato  group  on  the  2-
phenylindolylglyoxylamide scaffold. 
 Imaging using PET
PET (Positron Emission Tomography) is one of the most important imaging technique in 
the field of nuclear medicine, able to detect nanomolar metabolic variations. Originally 
used primarily as a research tool, PET has also had an increasingly important clinical role. 
There are four major areas of clinical application: oncology (diagnosis and monitoring of 
tumor,  follow  up  therapy,  tumor  prognosis  evaluation),  cardiology  (metabolism  and 
myocardial  viability),  neurology  (epilepsy,  schizophrenia,  Parkinson,  Alzheimer)  and 
psychology (“sensorial emotional images”). 38
PET is  a radiotracer imaging technique which uses small  amounts of tracer  compound 
labeled with positron-emitting radionuclides (called radiopharmaceutical or radiotracer) to 
help in the diagnosis of disease. Therefore, in PET short-lived radioactive drug emitting 
gamma rays is introduced in the subject of the study, either by injection or inhalation of a 
gas, and after an appropriate uptake period its concentration in tissue is measured by a PET 
scanner,  which produce an image showing its  distribution in the body.  41  PET looks at 
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physiological processes rather than anatomical structures and then gives only functional 
information. Therefore, it may be difficult to accurately localized anatomic structures or 
lesions that exhibit abnormal radiotracer accumulation. This limitation can be overcome 
using  PET/CT combination,  which  integrates  the  functional  tissue  information,  that  is 
provided by PET exam with the anatomical information, that can be obtained by structural 
imaging methods such as computed tomography (CT) exam, into one single exam. 42 
The physical bases of PET
All  the  positron  emitters  have  proton-rich  nuclei,  and,  in  an  attempt  to  stabilized 
themselves by getting rid of the excess protons and gaining neutrons in lieu, they may 
decay  via  positron  emission or  electron  capture,  both  of  which  are  isobaric  decay 
processes.44
In Table 2 are showed some isotopes which decay via positron emission. 
Isotope half-life (min) 
Maximum 
positron 
energy (MeV) 
Production 
method 
11C 20.3 0.96 cyclotron 
13N 9.97 1.19 cyclotron 
15O 2.03 1.70 cyclotron 
18F 109.8 0.64 cyclotron 
68Ga 67.8 1.89 generator 
82Rb 1.26 3.15 generator 
The  positron  is  an  antimatter  electron,  having  the  same  mass  but  a  positive  charge. 
Schematically, the positron decay process can be represented by: 
zX  z-1X* + e+ + υ 
There occurs a transmutation of elements: the daughter isotope has the same mass number 
but an atomic number reduced by one than the parent. This is accompanied by the emission 
of a neutrino, a particle with no mass or charge, and an highly interactive positron (small  
mass  and  positive  charge).  While  the  neutrino  escapes  without  interacting  in  the 
surrounding material,  the positron after travelling a short  distance (3-5 mm) is showed 
down by the scattering processes in the electron clouds of the surrounding environment. 
The distance traveled by the positron is known as its range and is function of the PET 
isotopes and then of the positron energy (18F, 11C, 15O, and 82Rb in water or tissue have a 
range between 2.6 and 16.5 mm). 42
As positrons travel through human tissues, there is  a continuous loss in kinetic energy 
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principally due to Coulomb interactions with electrons. When a positron reaches thermal 
energies, it combines with an electron either by annihilation, which produces two photons 
of 511 KeV each, or by the formation of a very short-lived particle called  positronium 
(Figure 11). 
 e+ + e-       γ  +  γ 
         
Figure 11. Positron emission and annihilation. 41
The positronium is unstable and susceptible to the  pick-off process, where it annihilates 
with another electron. In both cases the emitted pair of photons have an energy equivalent 
to the combined rest mass of an electron and a positron, and they are emitted at about 180°  
from each other. 
The  image  acquisition  is  based  on  the  detection  of  emitted  γ-rays  by  the  detectors 
surrounding the subject, which register the arrival of the annihilation photons as an event if 
the  two  detections  occur  within  a  narrow  timing  window  (typically  3-15  ns).  This 
“coincidence detection”, termed electronic collimation, is a fundamental requirement of 
detection because is  assumed that  the annihilation of  the same electronpositron couple 
takes place somewhere on the straight line drawn between the two detectors, termed line of 
response (LOR) or coincidence line. 
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Figure 12. Coincidence detection (author Jens Langner). 
These coincidence events provide information about the quantity and location of positrons: 
they are recorded and used in the image reconstruction through standard topographic
techniques (Figure 12).42
 
 Factors limiting the spatial resolution of PET42  
1. Detector size. The intrinsic detector spatial resolution also influences the quality of 
the reconstructed image. In modern PET scanners, the detectors use small crystal 
arrays coupled to large photodetectors. 
2. Non-colinearity of the annihilation photons. Owing to some residual momentum 
of the positron before it combines with the electron, the annihilation photons are 
emitted at not exactly 180° from each other, resulting in a coincidence line usually 
shifted of a angle smaller than 0.5° leading to blurring in the image. 
3. Positron range.  PET scanner does not provide information on the distribution of 
positron emission points, because it detects γ-rays emitted at the annihilation point. 
Positron emission point and annihilation point generally are not coincident because, 
as referred earlier, positrons travel some distance (range) within the surrounding 
material before it combines with an electron and emits the annihilation photons. 
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Pet radionucleotides
The  choice  of  the  radionuclide  to  be  used  in  a  PET exam is  influenced  by different 
considerations: 38
• availability of the radionuclide; 
•  physical characteristics;
• radiochemical issues; 
• radiopharmacological issues. 
As reported earlier in Table 2, all widely used PET nuclides have a very short half-life with 
limited availability: this on the one hand ensures a low dose released to the patient, but on 
the other side limits the clinical applicability on a routine basis. Therefore the production 
of PET nuclides has to be performed in a medical cyclotron on-site. Only fluorine-18 and 
gallium-68 do not  require  a  cyclotron in  PET sites.  38  PET radionuclides  are  generally 
obtained from the cyclotron (or generator) in a chemical form that is not predisposed for 
direct labeling reactions and thus are required several primary activation steps. Activated 
radionuclides  are  subsequently  incorporated  into  the  chemical  structure  of  the  vehicle 
molecule.38  A fundamental  parameter  that  influences  the imaging output  is  the  specific 
radioactivity of  the  PET tracer,  because  a  low specific  activity  would  lead  to  low or 
undetectable signals: in the other words, the lower the density of the target sites the higher 
the required specific activity. 42 
TSPO radioligands
    [11C]PK 11195 (11)          [11C]VC195 (12)        [11C]DAA1106 (13)  
  [11C]DPA713 (14)                    [11C]vinpocetine (15)  
Figure 13. Chemical structures of various PET tracers for imaging of the TSPO. 
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1-(2-chlorophenyl-N-methyl-N-(1-methylpropil)-3-isoquinolinecarboxamide (PK11195, 5) 
labeled with the positron emitter carbon-11 (t1/2 = 20.4 min., β+ = 99.8%) was the first 
TSPO radioligand to be used, first as racemate and later as R-enantiomer, in PET imaging 
of neurodegenerative pathologies, multiple sclerosis, brain tumors, cerebral infarct, and 
calcium channel anomalies in heart diseases. However, this radioligand presents several 
limitations, especially for brain imaging, including a high plasma protein binding and a 
poor penetration of the blood-brain barrier, which results in low levels of tracer in the 
brain. In addition, the high lipophilicity (logP = 3.4) of [11C]PK 11195 (11) causes a high 
level of nonspecific binding and a poor signal-to-noise ratios that complicate its quantifi-
cation and reduce its sensitivity in the in vivo evaluation of TSPO. Nevertheless, [11C]PK 
11195 (11) is still used as reference radioligand for the in vivo assessment of TSPO in PET 
studies. 39, 43  Subsequently, Matarrese et al.44 labeled new conformationally restrained 
quinoline-2-carboxamide derivatives analogues of PK 11195 (5) as potential radioligands 
to investigate TSPO in vivo. The radioligands were synthesized by [11C]-N-methylation 
from the corresponding desmethyl precursors. Among the compounds assayed, radioligand 
N-[11C]-VC195 (12), demonstrating a highly specific binding and tissue-to-blood ratios, 
emerged of potential interest for in vivo PET monitoring of neurodegenerative processes, 
but at the same time the high background levels of the tracer in the brain reduce its 
sensitivity.43 Even several phenoxyphenylacetamide derivatives, such as [11C]DAA1106 
(13), were radiolabeled with carbon-11 for PET imaging of TSPO. Zhang and co-workers 
45 observed that these radioligands pass across the blood-brain barrier, enter the rat brain 
and preferably distribute in the olfactory bulb and cerebellum, where there is the richest 
TSPO density in the rat brain. The binding specificity to the TSPO in the rat brain was 
demonstrated through the co-injection of non-radiolabeled TSPO-selective ligands 
resulting in a strong reduction of tracer up-take in the both brain regions. [11C]DAA1106 
(13) has been reported to be able to detect activation of microglia in several rat models of 
inflammations. 
11C]DPA713 (14) is a pyrazolopyrimidine derivative proposed as a PET tracer for the 
TSPO because has a lower lipophilicity, and higher selectivity and affinity (Ki = 4.7 nM) 
toward the TSPO than [11C]PK 11195 (Ki = 9.3 nM). This TSPO antagonist was evaluated 
in vivo in a healthy baboon and it was observed a high-er signal-to-noise ratios than [11C]-
(R)-PK 11195 in a rat model of neurodegeneration, which makes [11C]DPA713 suitable for 
quantification and studying of changes in the density of TSPO binding sites.46
Another example of TSPO radioligand is  [11C]vinpocetine (15), a Vinca minor alkaloid, 
that binds specifically the TSPO and used as a neuroprotective drug in the treatment and 
prevention of cerebrovascular diseases.  [11C]vinpocetine has showed a cerebral uptake 5-
fold higher than that of [11C]PK 11195 and a an he-terogeneous distribution in the brain of 
monkeys.  It  is  mainly  metabolized  in  [11C]ethanol,  that  is  showed  not  significantly 
contribute to the brain radioactivity pattern of [11C]vinpocetine.43
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     N1-Methyl-2-Phenylindol-3-Ylglyoxylamides
N,N-dialkyl-(2-phenylindol-3-yl)glyoxylamides  have  been  described  as  new potent  and 
selective TSPO ligands, and then suitable for the development of novel PET radioligands 
for TSPO. SAR data and previously reported pharmacophore/topological model hypothesis 
(Figure  14)  suggest  that  indole  NH should  not  be  involved  in  the  recognition  of  the 
receptor protein. 39
N1-methyl-2-phenylindol-3-ylglyoxylamides 
Figure 14. TSPO pharmacophore/topological model. 
In 2011 Pike et al. 39 reported a novel series of 2-phenylindol-3-ylglyoxylamides featuring 
a methyl substituent on the indole nitrogen and showing a high affinity for TSPO, with Ki 
values comparable to those of N1-unsubstitued parent compounds. The binding data of N1-
methylated indoles 16-26, expressed as Ki values and determined in rat kidney membranes 
by binding competition experiments against  [11C]PK 11195 as radioligand, are listed in 
Table 3, and compared with those of the N1-unbsustitued parent compounds (Id, Ie, Ig, Ih, 
Ij, In, Ip, Iv, Isss, Ittt, Iuuu, Izzz, Iaab) and the standard TSPO ligands 2, 5, and 6. 
All these compounds show Ki  values in the low nanomolar or subnanomolar range, from 
0.3 to 0.60 nM, essentially comparable with those of their unsubstitued counterparts, and 
these data validate the hypothesis that the insertion of the methyl group at the N 1  position 
does not significantly influence TSPO binding. The compound  24  is the only exception, 
with the lowest Ki value (Ki = 190 nM), while compounds 17 and 18 possess the highest 
affinity in the series (Ki = 0.30 nM) with a gain in activity of 25 and 4.6 fold respect to the 
unmethylated coun-terparts, Ie and Ig, respectively. 39
The high affinity of the compounds  16-26  made them suitable for the development of 
radioligands for imaging brain TSPO with PET. The best candidate to be labeled at the N1 
position with the positron emitter  carbon-11, by treatment  with  [11C]methyl  iodide and 
solid KOH in DMSO, is the compound 23 which shows the best combination of affinity 
(Ki =5.7 nM), adequately high toward TSPO, and lipophilicity (cLogP =3.95), with a low 
nonspecific binding and a lipophilic/hydrophilic balance suitably moderate for crossing the 
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blood-brain barrier and achieving an adequate brain concentration. 39
[11C]23 was synthesized by Pike and coworkers and tested with PET in rhesus monkeys, 
revealing a high proportion of radioligand to brain TSPO in the baseline experiments and 
furthermore the reversibility of this binding. Moreover, this radioligand was studied for the 
characteristics  of  its  binding  to  brain  membranes  collected  from  a  cohort  of  human 
subjects. 
In  conclusion,  this  research  group  has  discovered  a  promising  new  chemotype  for 
development of novel TSPO radioligands as biomarkers of neuroinflammation. 
Table 3. TSPO binding affinity of N,N-dialkylindolylglyoxylamide derivatives 16-26 compared to 
those of the unmethylated counterparts (Id, Ie, Ig, Ih, Ij, In, Ip, Iv, Isss, Ittt, Iuuu, Izzz, Iaab). 
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a] The  concentration  of  tested  compounds  that  inhibited  [3H]PK  11195  binding  to  rat  kidney 
mitochondrial membranes (IC50) by 50% was determined with six concentrations of the displacers, 
each  performed  in  triplicate.  Ki values  are  the  mean  ± SEM of  three  determinations.  [b] The 
inhibition percent of  [3H]flumazenil specific binding at 10  μM of the compound are the mean  ± 
SEM of five determinations. Ki values are the mean ± SEM of three determinations. [c] Data taken 
from ref. 39
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Introduction to Experimental Section
N,N-dialkyl-2-phenylindol-3-ylglyoxylamide derivatives, designed in 2004 by Primofiore 
et al.37, have shown a high affinity for TSPO in the nanomolar to subnanomolar range and a 
high selectivity for TSPO. The same research group has successively refined the TSPO 
pharmacophore/topological model through the synthesis and the biological evaluation of a 
library of novel 2-phenylindol-3- ylglyoxylamide derivatives of general formula (I).34
    Figura 14. N,N-dialkyl-2-phenylindol-3-ylglyoxylamides 
As  earlier  mentioned,  rationalizing  the  SARs  in  the  light  of  the  previously  reported 
pharmacophore/receptor model made up of three lipophilic pockets (L1, L3, L4) and an H-
bond donor group (H1), these authors have individuated four fundamental interactions: 5, 39
1. the second carbonyl group of the oxalyl bridge engages an H-bond with the donor site 
H1;               
2. the two lipophilic substituents R1 and R2 (linear or ramified alkyl, arylalkyl group) on 
the amide nitrogen interact hydrophobically with the L3 or L4 lipophilic pockets; 
3. the 2-phenyl group establishes π-stacking interactions within the L1 pocket. 
Taking  into  account  these  observations,  the  aim  of  this  work  is  to  refine  the  TSPO 
pharmacophore/topological  model  through the  synthesis  and biological  evaluation  of  a 
series of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides (II) bearing a polar group at the 4’-
position of the 2-phenyl ring (R3 = NH2, OH, COOH), and of a series of N,N-dialkyl-2-(3-
thienyl)indol-3-ylglyoxylamides  (III).  These  compounds  have  been  synthesized  as 
symmetrical amides featuring linear alkyl chains on the amide nitrogen (in particular  n-
propyl) to evaluate any changes in the interaction with the lipophilic pockets L3, L4 of the 
pharmacophore. The TSPO affinity of intermediary compounds featuring a OCH3 and a 
COOCH3 substituent in 4’-position has also been estimated. 
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Figure  15.  General  structures  of  N,N-dialkyl-2-phenylindol-3-ylglyoxylamides  (II)  and  N,N-
dialkyl-2-(3-thienyl)indol-3-ylglyoxylamides (III). 
The basal expression of TSPO is up-regulated in a number of neuropathologies, including 
gliomas  and  neurodegenerative  diseases,  in  various  forms  of  brain  injury  and 
inflammation, as well as in a variety of tumors. 
So, for this reasons, TSPO has been suggested as a promising diagnostic marker to image 
and  measure  the  TSPO  expression  and  distribution  levels,  and  thus  for  evaluation  of 
disease progression by means of specific fluorescent or radiolabeled ligands. In particular, 
PET imaging using TSPO ligands to label activated microglia offers quantitative measures 
of inflammation, and then can help to understand the regional brain distribution, stage and 
severity of neuroinflammation. 
Evaluating  a  novel  series  of  2-phenylindol-3-ylglyoxylamides  featuring  a  methyl 
substituent on the indole nitrogen the same research group, in collaboration with Pike and 
coworkers  39, has observed that the insertion of the methyl group at the N1-position does 
not  significantly  influence  TSPO  binding,  according  with  the  pharmacophore  model 
proposed. Therefore, these authors have developed novel radioligands for imaging brain 
TSPO with PET labeling the indole at the N1-position with the positron emitter carbon-11, 
and have indicated these compounds as promising new chemotype for development of 
novel TSPO radioligands as biomarkers of neuroinflammation. 
Therefore,  the  choice  to  insert  a  polar  group  in  the  scaffold  of  indolylglyoxylamide 
derivatives has been made with the purpose to improve the lipophilic/hydrophilic balance, 
envisaging  the  possibility  to  develop  novel  TSPO  radioligands  with  a  better 
pharmacokinetic  profile.  In  fact,  it  has  been previously observed that  highly lipophilic 
molecular probes show a high level of non-specific binding and thus a poor signal-to-noise 
ratios, a high plasma protein binding and thus a relatively poor penetration of the blood-
brain barrier, which results in a low levels of tracer accumulation in brain.43
At the same time, it has also been evaluated the influence on the TSPO binding of the 
insertion of the methyl group at the N1-position: N1-methylated indoles have been prepared 
and their Ki values compared with those of the N1-unsubstitued parent compounds and the 
standard TSPO ligands Ro 5-4864 (2), PK11195 (5) and alpidem (6). 
In this thesis work it has been prepared and evaluated the compounds 38 (2-(3-thienyl)), 40 
(R3  = NH2),  42  (R3 =  OH),  44  (R3 =  COOH),  methylated  at  the  N1-position,  and the 
corresponding N1-unmethylated 37 (2-(3-thienyl)), 39 (R3 = NH2), 41 (R3 = OH), 43 (R3 = 
COOH). It has also been estimated the Ki value of the intermediary N1-unmethylated com-
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pounds 31 (R3 = OMe), 32 (R3 = COOMe), and of the corresponding methylated 33 (R3 = 
OMe), 34 (R3 = COOMe). 
The  general  synthetic  procedures  employed  to  prepare  these  compounds  are  shown in 
Scheme 1 and 2. They involve, as first step, the synthesis of the 2-phenylindoles 29a-c and 
2-(3-thienyl)indole 35 through a one-step Fischer indole synthesis34 consisting in warming 
phenylhydrazine  hydrochloride  and  the  appropriate  acetophenone,  or  methyl  4-
acetylbenzoate,  or  acetylthiophene  directly  with  an  excess  of  acid  catalyst  PPA 
(polyphosphoric acid). The reaction mixture was then poured into ice and the precipitated 
solid was collected by filtration and purified by recrystallization from toluene. 
The indoles 29a-c and 35 were then acylated with oxalyl chloride in anhydrous ethyl ether 
at 0 °C to give the corresponding indolylglyoxylyl chlorides  30a-c  and  36, which were 
allowed to react in dry toluene solution and nitrogen atmosphere with dipropilammine in 
presence of triethylamine, in equimolar quantity so as neutralize the hydrochloridric acid 
formed during the reaction of condensation.37 The crude compounds, after washing with a 
solution of NaHCO3 dil. 5% and then with H2O to eliminate the amine not reacted, with 
HCl dil. 10% and again H2O to remove the excess of Et3N, were tritured at 0 °C with 
ethylic ether to yield the indolylglyoxylamides 1v, 31-32, and 37.
These  compounds  were  then  methylated  at  the  N1-position  through the  treatment  with 
sodium hydride and subsequent addition of an excess of methyl iodide in dry DMF.39 The 
reaction mixture was dripped into ice and the solid precipitated was collected by filtration, 
dried  and  subsequently  purified  by  recrystallization  from toluene  to  obtained  the  N1-
methylated indolylglyoxylamides  23,  33-34,  and  38.  Their  chemical-physical properties 
were determined, and their structures were confirmed by 1H-NMR [data reported in Table 
4 for compounds 31 and 33 (R3 = OMe), 32, and 34 (R3 = COOMe), Table 5 for 37-38 (2-
(3-thienyl)), data of compounds 1v and 23 (R1 = R2 =(CH2)2CH3; R3 = NO2) are reported in 
literature34]
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The synthesis of the target compounds 39 (R3 = NH2), 41 (R3 = OH), and 43 (R3 = COOH) 
was  achieved by the  procedures  outlined  in  Schemes  3,  4  and  5.  Starting  by the  N1-
methylated (23,  33,  34) and their parent unmethylated (1v,  31  ,32  ) indoles, previously 
prepared, we obtain, through appropriate reactions, the corresponding compounds featuring 
a polar group at the 4’-position of the 2-phenyl ring. 
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The Scheme 3, reported above, describes the general procedure for the synthesis of the 2-
phenylindolylglyolamide derivatives bearing a NH2 in para position at the 2-phenyl ring:41 
N,N-dialkyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide  derivatives  1v and  23  were 
catalytically hydrogenated over palladium to yield the relative amines  39  and  40. Their 
chemical-physical properties and 1H-NMR data are reported in Table 6. 
37
N
N
O
O
H
(CH2)2CH3
H3C(H2C)2
NO2
N
N
O
O
CH3
(CH2)2CH3
H3C(H2C)2
NO2
1)NaH
2)CH3I
anh.DMF
H2 / Pd-C
abs. EtOH
H2 / Pd-C
abs. EtOH
N
N
O
O
CH3
(CH2)2CH3
H3C(H2C)2
NH2
N
N
O
O
H
(CH2)2CH3
H3C(H2C)2
NH2
1v 23
39 40
Scheme 4
The  phenylindolylglyoxylamide  derivatives  featuring  a  OH group in  R3 (41,  42)  were 
achieved through a demethylation of the methoxy group47 (Scheme 4) in para position of 
the 2-phenyl ring with BBr3, added dropwise in nitrogen atmosphere to a stirred suspension 
of derivatives 31 or 33. Finally, methanol was added to the reaction mixture to hydrolyze 
the excess  of BBr3,  and crude compounds were recovered as a  solid  precipitated after 
evaporation under reduced pressure. Their chemical-physical properties and 1H-NMR data 
are reported in Table 6. 
Instead,  the  Scheme 5  reported the synthetic procedure to obtain compounds 43-44  by 
hydrolysis of the methyl ester48 in para position adding lithium hydroxide monohydrate to 
a  MeOH/H2O  (3:1)  solution  of  methyl  derivatives  32  or 34.  Their  chemical-physical 
properties and 1H-NMR data are reported in Table 6. 
38
N
N
O
O
H
(CH2)2CH3
H3C(H2C)2
OH
N
N
O
O
CH3
(CH2)2CH3
H3C(H2C)2
OMe
1)NaH
2)CH3I
anh.DMF
N
N
O
O
CH3
(CH2)2CH3
H3C(H2C)2
OH
N
N
O
O
H
(CH2)2CH3
H3C(H2C)2
OMe
     BBr3
anh. CH2Cl2
     BBr3
anh. CH2Cl2
31 33
41 42
Scheme 5
39
N
N
O
O
H
(CH2)2CH3
H3C(H2C)2
COOMe
1)NaH
2)CH3I
anh.DMF N
N
O
O
CH3
(CH2)2CH3
H3C(H2C)2
COOMe
LiOH   H2O           
MeOH / H2O
. LiOH   H2O           
MeOH / H2O
.
N
N
O
O
CH3
(CH2)2CH3
H3C(H2C)2
COOH
N
N
O
O
H
(CH2)2CH3
H3C(H2C)2
COOH
32
34
4443
Table 4. Yields, melting points, and spectral data of compounds 31, 32, 33 and 34.
n R1 = R2 R3 R4 yield (%) m.p. (°C) 
(recryst.
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
31 (CH2)2CH3 OCH3 H 52 121-126 
(toluene) 
0.64-0.79  ( m,  6H,  CH2CH2CH  3  ); 
1.21-1.26 ( m, 2H, CH2CH2CH3); 
1.39-1.47 ( m, 2H, CH2CH  2  CH3); 
2.93-3.06 ( 2t, 4H, J=7Hz,     
CH  2  CH2CH3);  3.83 ( s, 3H, OCH3); 
7.06 (d, 2H, J=8 Hz, ArH); 7.08-
7.29 (m, 2H, ArH); 7.42 (d, 1H, J=8 
Hz, ArH); 7.50 (d, 2H, J=8 Hz, 
ArH); 8.01 (d, 1H, J=8 Hz, ArH);
12.34 (s, 1H, NH exch. with D2O). 
C23H26N2O3 
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n R1 = R2 R3 R4 yield (%) m.p. (°C) 
(recryst.
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
32 (CH2)2CH3 COOCH3 H 65 139-141
(toluene) 
0.66-0.77 ( m, 6H, CH2CH2CH  3  ); 
1.20-1.27 ( m ,2H, CH2CH  2  CH3); 
1.45-1.49 ( m, 2H ,CH2CH  2  CH3); 
2.93-3.10 ( 2t, 4H, J=8Hz, 
CH  2  CH2CH3); 3.92 (1s, 3H, 
COOCH3); 7.27-7.31 (m, 2H, ArH); 
7.52 (d, 1H, J=8 Hz, ArH); 7.74 (d, 
2H, J=8 Hz, ArH);8.02-8.09 (m, 3H, 
ArH); 12.64 (s, 1H, NH exch. with 
D2O). 
C24H26N2O4 
 
33 (CH2)2CH3 OCH3 CH3 69 135-137 
(toluene) 
0.67-0.75 (m, 6H, CH2CH2CH  3  ); 
1.03-1.14 (m, 2H, CH2CH  2  CH3); 
1.41-1.52 (m, 2H, CH2CH  2  CH3); 
2.71-2.97 (2t, 4H, J=7 Hz, 
CH2CH2CH3); 3.50 (s, 3H, NCH3); 
3.84 (s, 3H, OCH3);7.07 (d, 2H, J=8 
Hz, ArH); 7.32-7.39 (m, 4H, ArH); 
7.63 (d, 1H, J=8 Hz, ArH); 8.21(d, 
1H, J=8,ArH). 
C24H28N2O3 
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34 (CH2)2CH3 COOCH3 
 
CH3 56 135-137 
(toluene) 
0.64-0.75 (m, 6H, CH2CH2CH  3  ); 
1.03-1.07 (m, 2H, CH2CH  2  CH3); 
1.37-1.60 (m, 2H, CH2CH  2  CH3); 
2.73-2.98 (2t, 4H, J=8 Hz, 
CH  2  CH2CH3); 3.52 (s, 3H, NCH3); 
3.92 (s, 3H, COOCH3); 7.25-7.42 
(m, 2H, ArH); 7.61-7.65 (m, 3H, 
ArH); 8.06-8.20 (m, 3H, ArH). 
C25H28N2O4 
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Table 5. Yields, melting points, and spectral data of compounds 37, 38.
n R1 = R2 R4 yield (%) m.p. (°C) 
(recryst. 
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
37 (CH2)2CH3 H 78 68-71 0.65 (t, 3H, J=8 Hz, CH2CH2CH  3  ); 
0.81 (t, 3H, J=8 Hz, CH2CH2CH  3  ); 
1.30-1.50 (m, 4H, CH2CH  2  CH3); 
3.00-3.14 (m, 4H, CH  2  CH2CH3); 
7.21-7.27 (m, 2H, ArH); 7.46-7.50 
(m, 2H, ArH); 7.69-7.73 (m, 1H, 
ArH); 7.91 (d, 1H, J=7 Hz, ArH); 
8.13 (d, 1H, J=2 Hz, ArH); 12.45 (s, 
1H, NH exch. with D2O). 
C20H22N2O2S 
38 (CH2)2CH3  CH3 65 118-121 
 
0.67-0.81 (m, 6H, CH2CH2CH3); 
1.24-1.48 (m, 4H, CH2CH2CH3); 
2.80-3.00 (2t, 4H, J=8 Hz, 
CH2CH2CH3); 3.54 (s, 3H, NCH3); 
7.24 (d, 1H, J=7 Hz, ArH); 7.32-7.38 
(m, 2H, ArH); 7.65 (d, 1H, J=7 Hz, 
ArH); 7.72-7.79 (m, 2H, ArH); 8.21 
(d, 1H, J=7 Hz, ArH). 
C21H24N2O2S 
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Table 6. Yields, melting points, and spectral data of compounds 39-44. 
n R1 = R2 R3 R4 yield (%) m.p. (°C) 
(recryst. 
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
39 (CH2)2CH3 NH2 
 
H 52 197-198 
(toluene) 
0.63-0.84 (m, 6H, CH2CH2CH  3  ); 
1.29-1.37 (m, 2H, CH2CH  2  CH3); 
1.41-1.49 (m, 2H, CH2CH  2  CH3); 
2.97- 3.08 (2t, 4H, J=7 Hz, 
CH  2  CH2CH3); 5.57 (s, 2H, NH2 
exch. with D2O); 6.62 (d, 2H, J=8 
Hz, ArH); 7.17-7.43 (m, 5H, ArH); 
7.92-7.97 (m, 1H, ArH); 12.09 (s, 
1H, NH exch. with D2O). 
C22H25N3O2 
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n R1 = R2 R3 R4 yield (%) m.p. (°C) 
(recryst. 
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
40 (CH2)2CH3 NH2 CH3 82 178-180
(toluene) 
0.67-0.77 (m, 6H, CH2CH2CH  3  )  ; 
1.12-1.23 (m, 2H, CH2CH  2  CH3); 
1.40-1.51 (m, 2H, CH2CH  2  CH3); 
2.72- 2.97 (2t, 4H, J=8 Hz, 
CH  2  CH2CH3); 3.51 (s, 3H, NCH3); 
7.16-7.33 (m, 6H, ArH); 7.59 (d, 
1H, J=8 Hz, ArH); 8.19 (d, 1H, 
J=8 Hz, ArH); 8.56 (d, 2H, J=20 
Hz, NH2 exch. with D2O); 
C23H27N3O2 
 
41 (CH2)2CH3 OH H 59 210-212 
              (toluene) 
0.64-0.82 (m, 6H, CH2CH2CH  3  )  ; 
1.27-1.46 (m, 4H, CH2CH  2  CH3); 
2.95-3.02 (2t, 4H, J=8 Hz, 
CH  2  CH2CH3); 6.86 (d, 2H, J=8 
Hz, ArH); 7.17-7.25 (m, 2H, ArH); 
7.40 (d, 3H, J=8 Hz, ArH); 8.01 
(d, 1H, J=7 Hz, ArH); 9.89 (s, 1H, 
OH exch. with D2O); 12.27 (s, 1H, 
NH exch. with D2O). 
C22H24N2O3 
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n R1 = R2 R3 R4 yield (%) m.p. (°C) 
(recryst.
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
42 (CH2)2CH3 OH CH3 75 211-214 0.67-0.77 (m, 6H, CH2CH2CH  3  )  ; 
1.09-1.21 (m, 2H, CH2CH  2  CH3); 
1.41-1.52 (m, 2H, CH2CH  2  CH3); 
2.72-2.96 (2t, 4H, J=8 Hz, 
CH  2  CH2CH3); 3.50 (s, 3H, 
NCH3); 6.88 (d, 2H, J=8 Hz, 
ArH); 7.23 (d, 2H, J=8 Hz, ArH); 
7.33-7.36 (m, 2H, ArH); 7.62 (d, 
1H, J=8 Hz, ArH); 8.21 (d, 1H, 
J=8 Hz, ArH); 9.88 (s, 1H, OH 
exch. with D2O). 
C23H26N2O3 
 
 
43 (CH2)2CH3 COOH H 85 292-294 0.64-0.75 (m, 6H, CH2CH2CH  3  ); 
1.15-1.26 (m, 2H, CH2CH  2  CH3); 
1.43-1.47 (m, 2H, CH2CH  2  CH3); 
2.88-3.15 (2t, 4H, J=8  Hz, 
CH  2  CH2CH3); 7.27-7.31 (m, 2H, 
ArH); 7.51 (d, 1H, J=8 Hz, ArH); 
7.71 (d, 2H, J=8 Hz, ArH); 8.04 
(d, 3H, J=8 Hz, ArH); 12.63 (s, 
1H, NH exch. with D2O). 
C23H24N2O4 
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n R1 = R2 R3 R4 yield (%) m.p. (°C) 
(recryst.
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
44 (CH2)2CH3 COOH CH3 68 287-290 0.68-0.72 (m, 6H, CH2CH2CH  3  ); 
0.95-1.20 (m, 2H, CH2CH  2  CH3); 
1.37-1.61 (m, 2H, CH2CH  2  CH3); 
2.70-3.11 (2t, 4H, J=8Hz, 
CH  2  CH2CH3); 3.37 (s, 3H, NCH3); 
7.28-7.45 (m, 2H, ArH); 7.61 (d, 2H, 
J=8 Hz, ArH); 7.72 (d, 1H, J=8 Hz, 
ArH); 8.08 (d, 2H, J=8 Hz, ArH); 
8.20 (d, 1H, J=8 Hz, ArH).
C24H26N2O 
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    Biological Studies 
All products synthesized during this thesis work were assayed by the research group of 
Prof. Claudia Martini, Department of Pharmacy, University of Pisa. 
The  binding  affinity  at  TSPO  of  all  the  newly  synthesized  compounds  37-44  was 
determined in rat kidney membranes by binding competitions experiments against [3H]PK 
11195  as  radioligand.37  For  binding  studies,  crude  mitochondrial  membranes  were 
incubated  with  [3H]PK11195  (0.6  nM)  in  the  presence  of  the  test  compound  in  the 
concentration range (0.05 nM-10 μM) in Tris-HCl buffer (50 mM, pH 7.4), as described in 
literature. 37 For the active compounds, the IC50 values were determined and Ki values were 
derived according to the Cheng-Prusoff equation. 49
Tables 7 and 8 reports the TSPO binding affinity data expressed as Ki values (nM), of a 
number of compounds synthesized in this thesis work, together with the Ki values of the 
standard Ro 5-4864 (2), PK11195 (5), and alpidem (6), and of the reference compounds 1d 
and 16. 
It should be noted that all compounds show good to high affinity for TSPO, with Ki values 
in the nanomolar range. 
Analysis of these preliminary data allowed to make few main considerations: 
1) The insertion of a methoxy group at the 4’-position of Id yields compound 31 showing a 
slight increase in TSPO affinity (Id Ki = 12.2 nm, 31 Ki= 5.82 nM). 
2)  The  insertion  of  hydrophilic  substituents  (OH,  NH2,  COOH)  on  the  2-phenyl  ring 
(compounds  39,  41,  and  43)  does  not  determine  any  significant  improvement  of  the 
affinity,  suggesting the interaction at the level of the L1 pocket is mostly lipophilic.  In 
particular, the insertion of a OH group at the 4'-position of the 2-phenyl ring is tolerated for 
TSPO affinity (Id, Ki = 12.2 nm, 41 Ki = 16.13 nM). Conversely, a decrease of the binding 
affinity is observed introducing a NH2 or, to a major extent, a COOH group (Id Ki = 12.2 
nm, 39 Ki = 44.4 nM, 43 Ki = 343 nM).
3) The insertion of a lipophilic subsituents (COOCH3, thiophene ring), on the 2-phenyl ring 
(compound  32 ) shows a low increase in TSPO affinity ( Id Ki = 12.2 nm, 32 Ki = 3.101 
nM), while for compound 37, shows an elevate increase in TSPO affinity (37 Ki = 1.234 
nm). Compound 37 results the most potent compound among the products tested.
4)  Insertion of a  methyl  group on the indole N1-nitrogen produces  different  effects  on 
TSPO affinity in dependence of the substituent at 4’-position. From the comparison of the 
N1-methyl  derivatives  with  their  corresponding  N1-unmethylated,  the  following 
observations could be drawn: 
• the affinity is substantially maintained when the 2-phenyl ring is unsubstituted (Id 
Ki = 12.2 nm, 16 Ki = 19.5 nM) or features a 4’-methoxy group (31 Ki = 5.82 nm, 
33 Ki = 14.65 nM) or when is present a  COOCH3 group (32 Ki = 3.101 nm, 34 Ki 
= 3.483 nm). 
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• a significant improvement in TSPO affinity was observed when a NH2 group is 
present at 4’-position (39 Ki = 44.4 nm, 40 Ki = 5.63 nM), while a decrease was 
noticed when a thiophene group is present on the 2-indole ring (37 Ki = 1.234 nm, 
38 Ki = 21.17 nM).
• the contemporary presence of N1-methyl and 4’-OH moieties yields a detrimental 
effect on TSPO affinity (41 Ki = 16.13 nm, 42 Ki = 143.3 nM).
• the N1-unmethylated compound (43), featuring a 4'-COOH group, presents a low 
activity and the introduction of the methyl group (44) cause the loss of the activity.
Summarizing, it should be speculated that the substitutions at 1'- and 4’-positions seem to 
significantly modulate TSPO affinity in an interdependent and not additive way. 
49
Table 7. Preliminary data of the receptor binding affinity for TSPO. 
n R1 = R2 R3 R4 TSPO 
Ki (nM)[a] 
Id (CH2)2CH3 H H 12.2±1.0 
16 (CH2)2CH3 H CH3 19.5±1.5 
31 (CH2)2CH3 OCH3 H 5.82±0.5 
33 (CH2)2CH3 OCH3 CH3 14.65±1.5 
32 (CH2)2CH3 COOCH3 H 3.101±0.3
34 (CH2)2CH3 COOCH3 CH3 3.483±0.35
39 (CH2)2CH3 NH2 H 44.4±5.0
40 (CH2)2CH3 NH2 CH3 5.63±0.6 
41 (CH2)2CH3 OH H 16.13±1.0 
42 (CH2)2CH3 OH CH3 143.3±15 
43 (CH2)2CH3 COOH H 343.0±10 
44 (CH2)2CH3 COOH CH3 Not active
Ro 5-4864 23.0±3.0
PK 11195 9.30±0.5
alpidem 0.5 – 7 
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Table 8 Preliminary data of the receptor binding affinity for TSPO. 
n R1 = R2 R3 R4 TSPO 
Ki (nM)[a] 
Id (CH2)2CH3 H H 12.2±1.0 
16 (CH2)2CH3 H CH3 19.5±1.5 
37 (CH2)2CH3 thiophene ring H 1.234±0.12
38 (CH2)2CH3 thiophene ring CH3  21.17±0.2
Ro 5-4864 23.0±3.0
PK 11195 9.30±0.5
alpidem  0.5 – 7 
a]The  concentration  of  tested  compounds  that  inhibited  [3H]PK  1195  binding  to  rat  kidney 
mitochondrial membranes (IC50) by 50% was determined with six concentrations of the displacers, 
each performed in triplicate. Ki values are the mean ±SEM of three determinations. 
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Experimental Section
Materials and Methods
Melting  points  were  determined  using  a  Reichert  Köfler  hot-stage  apparatus  and  are 
uncorrected.  Routine  nuclear  magnetic  resonance  spectra  were  recorded  in  DMSO-d6 
solution on a Varian Gemini 200 spectrometer operating at 200 MHz. Evaporation was 
performed in vacuo (rotary evaporator). Analytical TLC was carried out on Merck 0.2 mm 
precoated  silica  gel  aluminum sheets  (60  F-254).  Silica  gel  60  Merck (230-400 mesh 
ASTM) was used for column chromatography.  Anhydrous reactions  were performed in 
flame-dried glassware under N2. All compounds showed ≥ 95% purity.
All  reagents  used  were  obtained  from  commercial  sources.  All  solvents  were  of  an 
analytical grade. 
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Experimental Section
General procedure for the synthesis of: 
2-phenyl-1H-indole derivatives (29a, 29b) 
methyl 4-(1H-indol-2-yl)benzoate derivative (29c)
2-(3-thienyl)-1H-indole derivative (35)
1 g of polyphosphoric acid (PPA) was added to a mixture of phenylhydrazine chlorhydrate 
(5.0 mmol) and methyl 4-acetylbenzoate (5.0 mmol), or the appropriate acetophenone or 
acetylthiophene (5.0 mmol). The reaction was maintained at 75°C for 30 min for 29a at 
120°C for 4 h for  29b and 35 and at 60°C for 4 h for compound 29c. When the starting 
material was disappeared, the reaction mixture was poured into ice and the precipitated 
solid  was  collected  by  filtration.  All  products  were  purified  by  recrystallization  from 
toluene.
Yield, melting point, and spectral data of compound 29a were reported in literature.34
2-(4-methoxyphenyl)-1H-indole (29b). Yield: 84%; m. p.: 231-234 °C; 1H-NMR (DMSO-
d6, ppm): 3.80 (s, 3H, OCH3); 6.76 (d, 1H, J = 1.8 Hz, ArH); 6.96-7.09 (m, 4H, ArH); 7.36 
(d, 1H, J = 8 Hz, ArH); 7.49 (d, 1H, J = 7.2 Hz, ArH); 7.77-7.81 (m, 2H, ArH); 11.40 (s, 
1H, NH exch. with D2O). 
Methyl  4-(1H-indol-2-yl)benzoate  (29c).  Yield:  78%;  m.  p.:  204-207  °C;  1H-NMR 
(DMSO-d6, ppm): 3.87 (s, 3H, COOCH3); 7.02-7.15 (m, 3H, ArH); 7.43 (d, 1H, J=8 Hz, 
ArH); 7.57 (d, 1H, J=8 Hz, ArH); 8.02 (s, 4H, ArH); 11.73 (s, 1H, NH exch. with D2O).
2-(3-thienyl)-1H-indole (35). Yield: 89%; m. p.: 243-245 °C; 1H-NMR (DMSO-d6, ppm): 
6.76 (d, 1H, J = 0.8 Hz, ArH); 6.94-7.12 (m, 2H, ArH); 7.37 (d, 1H, J = 8 Hz, ArH); 7.51 
(d, 1H, J = 8 Hz, ArH); 7.59-7.67 (m, 2H, ArH); 7.87 (t, 1H, J = 1.5 Hz, ArH).  
General procedure for the synthesis of: 
(2-phenylindol-3-yl)glyoxylyl chloride derivatives (30a, 30b) 
methyl 4-(3-chloroglyoxylylindol-2-yl)benzoate derivative (30c) 
[2-(3-thienyl)indol-3-yl]glyoxylyl chloride derivative (36)
Oxalyl chloride (8.0 mmol) was added dropwise at 0°C to a well-stirred mixture of the 
appropriate indole 29a-c or 35 (4.0 mmol) in freshly distilled diethyl ether (10 mL). The 
mixture was maintained at room temperature for 2-24 h (TLC analysis: chloroform). A 
solid precipitate was obtained in the case of compounds 30b and 30c, which was collected 
by vacuum filtration, and immediately used in the subsequent reaction. Instead, starting by 
compounds 29a and 35, it was not observed any formation of precipitate: thus, the solvent 
of reaction was evaporated under reduced pressure, and the generated solid was washed 
with portions of anhydrous diethyl ether to give the correspondent acyl chlorides 30a and 
36.
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[2-(4-nitrophenyl)indol-3-yl]glyoxylyl chloride (30a). Yield: 60% 
[2-(4-methoxyphenyl)indol-3-yl]glyoxylyl chloride (30b). Yield: 72% 
Methyl 4-(3-chloroglyoxylylindol-2-yl)benzoate (30c). Yield: 80% 
[2-(3-thienyl)indol-3-yl]glyoxylyl chloride (36). Yield: 65%   
General procedure for the synthesis of: 
N,N-dialkyl-(2-phenylindol-3-yl)glyoxylamide derivatives (1v, 31) 
methyl 4-(3-dialkylaminoglyoxylylindole-2-yl)benzoate derivatives (32) 
N,N-dialkyl-[2-(3-thienyl)indol-3-yl]glyoxylamide derivatives (37) 
A solution of dipropylamine (2.0 mmol) in 5 mL of dry toluene was added dropwise to a 
stirred suspension, cooled at 0°C, of the (2-phenylindol-3-yl)glyoxylyl chloride derivatives 
30a-30b,  or  methyl  4-(3-chloroglyoxylylindol-2-yl)benzoate  derivative  30c,  or  [2-(3-
thienyl)indol-3-yl]glyoxylyl  chloride derivative  36  (2.0  mmol)  in  50  mL of  the  same 
solvent, followed by the addition of a solution of triethylamine (2.0 mmol). The reaction 
mixture  was  left  under  stirring  for  2-24  h  at  room  temperature  (TLC  analysis  with 
appropriate  eluent),  and  then  filtered.  The  collected  precipitate  was  triturated  with  a 
NaHCO3 5% aqueous solution,  washed with  water,  and collected  again  to  give  a  first 
portion  of  crude  product.  The  toluene  solution  was  instead  removed  under  reduced 
pressure, and the oily residue obtained was extracted with CHCl3 and purified by washing 
with 1) a solution of NaHCO3 dil. 5%; 2) H2O; 3) HCl dil. 10%; and finally 4) H2O. After 
drying with MgSO4, the chloroform solution was evaporated to dryness, and the residue 
was tritured at 0 °C with ethylic ether to yield the crude product, that was collected by 
filtration. In the case of less soluble products, the crude compound precipitates together 
with the triethylamine hydrochloride and was collected, after washing with a solution of 
NaHCO3 dil. 5%, and dried over P2O5 in vacuo.
All products generally did not require additional purification steps, but in the case of dirty 
compounds they were purified by recrystallization from toluene; only the compound  1v, 
N,N-di-n-propyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide,  was  purified  by  flash 
chromatography (CHCl3 as eluent), as reported in literature.34
Yields, melting points, and spectral data of compounds 31 and 32 are listed in Table 4, 37 
in Table 5, while those of compound 1v were reported in literature.34
General procedure for the synthesis of: 
N,N-dialkyl-(N1-methyl-2-phenylindol-3-yl)glyoxylamide derivatives (23, 33) 
methyl 4-(N1-methyl-3-dialkylaminoglyoxylylindol-2-yl)benzoate derivatives (34) 
N,N-dialkyl-2-[N1-methyl-(3-thienyl)indol-3-yl]glyoxylamide derivatives (38) 
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Sodium hydride (0.2 mmol, 60 % dispersion in mineral oil) was added portionwise, under 
a  nitrogen  atmosphere,  to  an  ice-coooled  solution  of  the  appropriate  N,N-dialkyl-(2-
phenylindol-3-yl)glyoxylamide derivatives 1v,  31,  32 and  37  in dry DMF (3 mL). Once 
hydrogen evolution ceased, an excess of methyl iodide (0.6 mmol) was quickly added at 0 
°C. The reaction was maintained under stirring at room temperature until the disappearance 
of starting material (TLC analysis with appropriate eluent). The mixture was then dripped 
into  ice  and  the  solid  precipitated  was  collected  by  filtration,  dried  and  subsequently 
purified by recrystallization from toluene. Only the compound  23 was purified by flash 
chromatography (CHCl3 as eluent). 39
Yields, melting points, and spectral data of compounds 33 and 34 are listed in Table 4, 38 
in Table 5, while those of compound 23 were reported in literature. 39 
General procedure for the synthesis of: 
N,N-dialkyl-[2-(4-aminophenyl)indol-3-yl]glyoxylamide derivatives (39, 40) 
Pd/C  10%  (0.05  g)  was  added  to  a  suspension  of  the  appropriate  N,N-dialkyl-[2-(4-
aminophenyl)indol-3-yl]glyoxylamide derivatives  1v  or  23  (0.65  mmol)  in  150  mL of 
absolute ethanol. The mixture was hydrogenated under stirring for 5 h at room temperature 
and reduced pressure. Once hydrogen absorption ceased, the catalyst was filtered off and 
the ethanolic solution was evaporated to dryness at reduced pressure. 
All products were purified by recrystallization from toluene. Yields, melting points, and 
spectral data of compounds 39 and 40 are listed in Table 6. 
General procedure for the synthesis of: 
N,N-dialkyl-[2-(4-hydroxyphenyl)indol-3-yl]glyoxylamide derivatives (41, 42) 
To  a  stirred  suspension  of  N,N-dialkyl-[2-(4-methoxyphenyl)indol-3-yl]glyoxylamide 
derivatives  31or  33 (0.5 mmol) in 10 mL of dry dichloromethane cooled at -10 °C were 
added dropwise 0.2 mL of BBr3. The mixture was left under stirring for 30 min. at -10 °C, 
and  subsequently  at  room temperature  for  1h  under  nitrogen  atmosphere.  Finally,  the 
solution was cooled again, and was added 5 ml of methanol to hydrolyze the excess of 
BBr3.  The  solvent  was  evaporated  at  reduced  pressure,  and  the  solid  precipitate  was 
washed several times with methanol. 
The residues obtained were purified by recrystallization from toluene.
Yields, melting points, and spectral data of compounds 41 and 42 are listed in Table 6.  
General procedure for the synthesis of: 
4-(3-dialkylaminoglyoxylylindol-2-yl)benzoic acid derivatives (43, 44) 
Lithium hydroxide monohydrate (0.3 mmol) was added to a suspension of  methyl 4-(3-
dialkylaminoglyoxylylindol-2-yl)benzoate derivatives 32 or 34 (0.5 mmol) in 20 mL of a 
MeOH/H2O (3:1) solution. The mixture was stirred under reflux at 80 °C overnight (TLC 
analysis with appropriate eluent). Subsequently, the solid precipitate was eliminate through 
vacuum filtration, and the solution was acidified with HCl dil.  10% to pH 5. The acid 
precipitated in the solution was collected by filtration and generally did not needed any 
further purification. 
Yields, melting points, and spectral data of compounds 43 and 44 are listed in Table 6. 
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